Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
2015 Leerink Global Healthcare Conference (Live)
02/11/15 at 8:50 a.m. ET
2015 Leerink Global Healthcare Conference
Wednesday, February 11, 2015 8:50 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$68.51
Change (%) Stock is Down 1.35 (1.93%)
Volume2,326,655
Data as of 01/30/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
DateTitle 
01/14/15Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy
CARLSBAD, Calif., Jan. 14, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).  The open-label extension study of ISIS-SMNRx is offered to those children with SMA who have completed dosing in Isis' previous studies.  In this study, children with SMA are receiving a 12 ... 
Printer Friendly Version
01/09/15Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics
New Agreement Includes Cross-License on Four Disease Targets, Providing Each Company Exclusive RNA Therapeutic License Rights for Two Programs CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), leaders in RNA-targeted therapeutics, announced today they have formed a new agreement, extending their existing strategic partnership – formed originally in ... 
Printer Friendly Version
01/08/15Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance
Strong Performance represents success of novel business strategy CARLSBAD, Calif., Jan. 8, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Company expects to significantly improve upon its 2014 financial guidance.  The Company expects to end 2014 with a pro forma net operating loss (NOL) in the mid to high teens and more than $725 million in cash.  The significantly improved financial performance of the Company in 2014 was a result of the successful exe... 
Printer Friendly Version
01/06/15Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Isis-owned Subsidiary Launched to Conduct Development and Commercialization of Isis' Lipid Franchise Drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the appointment of Paula Soteropoulos as president and chief executive officer (CEO) of Akcea Therapeutics, the Isis-owned, lipid franchise subsidiary responsible for the development and commercialization of Isis' lipid drugs, ISIS-APOCIIIRx, ISIS-APO(a)Rx, ISIS-A... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
02/11/15 8:50 a.m. ET
2015 Leerink Global Healthcare Conference
LocationNew York, NY US
02/21/15
through
02/25/15
38th ARO MidWinter Meeting
LocationBaltimore, MD
02/23/15
through
02/24/15
Theo Murphy International Scientific Meeting
LocationBuckinghamshire, United Kingdom
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up